Our Services
Medical Information
Helpful Resources
Published on: 3/18/2026
When SSRIs or SNRIs don't work, the evidence-based next steps typically begin with a careful reassessment for misdiagnosis, adherence issues, and medical contributors to depression. From there, treatment usually moves to either switching antidepressant classes (bupropion, mirtazapine, TCAs, or MAOIs) or augmenting your current medication with agents like aripiprazole, quetiapine, lithium, T3, or bupropion—alongside psychotherapy.
If these strategies fall short, newer options such as esketamine or ketamine, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT) may be considered. Urgent care is essential if you experience suicidal thoughts, psychosis, or an inability to function.
Because the right next step depends heavily on your specific symptoms, medical history, and how you've responded to prior treatment, a personalized assessment is the smartest starting point. Take a free, instant, online symptom check to better understand what's going on and get clear guidance on how to navigate your next steps with confidence.
Reviewed for medical accuracy: 07/09/2026
If you've gone through failed trials of SSRI and SNRI, what is next can feel like an overwhelming question. You may have tried one antidepressant, then another, and still feel stuck. This is more common than many people realize — and importantly, it does not mean you are out of options.
Modern depression treatment has evolved. There is now a clear, evidence-based roadmap for what comes after unsuccessful SSRI or SNRI treatment. Below, we'll walk through what "failed treatment" really means, why medications sometimes don't work, and what your next steps may look like.
Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are typically first-line treatments for major depressive disorder.
A trial is generally considered "adequate" when:
A "failed trial" usually means:
If you've had two or more failed trials of SSRI and SNRI, doctors may describe this as treatment-resistant depression (TRD). This term sounds alarming, but it simply means first-line medications were not enough — not that treatment won't work.
Depression is not one-size-fits-all. It involves complex brain chemistry, genetics, inflammation pathways, stress hormones, life stressors, and more.
Common reasons for inadequate response include:
Before moving forward, a thorough reassessment is critical. Understanding your full symptom picture is essential for finding the right treatment path — if you want to assess whether your symptoms align with depression or explore patterns you may not have noticed, Ubie's free AI-powered symptom checker provides a comprehensive evaluation in just minutes that you can bring to your next doctor's visit.
When first-line antidepressants do not work, physicians follow several evidence-based pathways.
Before adding or switching medications, doctors often:
Misdiagnosis is more common than people think. Treating bipolar depression with antidepressants alone, for example, can worsen symptoms.
If SSRIs and SNRIs were ineffective, your doctor may suggest switching to a medication with a different mechanism of action.
Options include:
Switching classes can be surprisingly effective because different brain pathways are involved.
Instead of replacing your antidepressant, your doctor may add another medication to boost its effects.
Common augmentation strategies:
Augmentation is one of the most evidence-supported strategies after failed trials of SSRI and SNRI.
Medication alone is often not enough.
Evidence-based therapies include:
Studies consistently show that combining medication with therapy improves outcomes more than medication alone — especially after initial medication failure.
In the past decade, several newer treatments have changed the roadmap.
ECT may sound intimidating, but in severe or life-threatening depression, it can be life-saving.
While not a replacement for medical treatment, these factors significantly influence outcomes:
Inflammation, metabolic health, and circadian rhythm all affect mood regulation.
If you are experiencing:
You should seek immediate medical care. Depression can become life-threatening. Speak to a doctor, go to the nearest emergency department, or call emergency services right away.
There is no benefit in waiting when safety is involved.
If you've had failed trials of SSRI and SNRI, what is next is not "nothing." It is usually a structured, stepwise approach that includes:
Studies show that many people who do not respond to their first or second medication eventually do respond with adjusted strategies.
It may take time. It may require specialist care, such as a psychiatrist with experience in treatment-resistant depression. But options remain.
Most importantly: do not navigate this alone. If your depression feels persistent, worsening, or dangerous, speak to a doctor. With the right roadmap, many people who experience failed trials of SSRI and SNRI eventually find a treatment plan that works.
(References)
* Al-Harbi MM, Al-Marri SM, El-Metwally A, Ghouri N, Al-Majid K. Treatment-Resistant Depression: A Comprehensive Review of Definition, Risk Factors, and Management Strategies. Neuropsychiatr Dis Treat. 2023 Sep 5;19:1921-1936. doi: 10.2147/NDT.S425338. PMID: 37675545.
* Fidalgo N, Silva M, Santos A, Parente S, Oliveira E, Castelo-Branco J, Saraiva V, Salgado D. Augmentation Strategies for Treatment-Resistant Depression: A Systematic Review. J Clin Med. 2022 Jul 26;11(15):4340. doi: 10.3390/jcm11154340. PMID: 35928682.
* Ochs-Ross R, Krystal JH, Sanacora G, De Vriendt K, Danchenko N, Yan M, Fu DJ, Singh JB. Esketamine for treatment-resistant depression: a systematic review and meta-analysis. CNS Spectr. 2022 Feb;27(1):86-98. doi: 10.1017/S109285292000073X. PMID: 32959648.
* Almasi N, Aftab A. Neuromodulation for treatment-resistant depression: A review of current practices and future directions. Curr Psychiatry Rep. 2021 Jun 25;23(8):54. doi: 10.1007/s11920-021-01267-0. PMID: 34212959.
* Ionescu DF, Ochs-Ross R, Danchenko N, Fu DJ, Krystal JH, Sanacora G. Novel Pharmacotherapeutic Approaches for Treatment-Resistant Depression: A Narrative Review. CNS Spectr. 2024 Apr;29(2):112-124. doi: 10.1017/S109285292300067X. PMID: 37778716.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.